VCYT Quote, Financials, Valuation and Earnings

Fonar has a net margin of 6.16% compared to Veracyte's net margin of 9.23%. Veracyte's return on equity of 2.85% beat Fonar's return on equity of 5.33%.

Veracyte has a consensus price target of $40.89, signalling upside risk potential of 54.94%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Veracyte has a beta of 2.093, which suggesting that the stock is 109.267% more volatile than S&P 500. In comparison Fonar has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than Fonar quarterly revenues of $27.2M. Veracyte's net income of $7M is higher than Fonar's net income of $2.5M. Notably, Veracyte's price-to-earnings ratio is 64.37x while Fonar's PE ratio is 11.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.50x versus 0.88x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

Insight Molecular Diagnostics has a net margin of 6.16% compared to Veracyte's net margin of -312.02%. Veracyte's return on equity of 2.85% beat Insight Molecular Diagnostics's return on equity of -693.81%.

Veracyte has a consensus price target of $40.89, signalling upside risk potential of 54.94%. On the other hand Insight Molecular Diagnostics has an analysts' consensus of -- which suggests that it could grow by 27.75%. Given that Veracyte has higher upside potential than Insight Molecular Diagnostics, analysts believe Veracyte is more attractive than Insight Molecular Diagnostics.

Veracyte has a beta of 2.093, which suggesting that the stock is 109.267% more volatile than S&P 500. In comparison Insight Molecular Diagnostics has a beta of 0.970, suggesting its less volatile than the S&P 500 by 3.025%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Insight Molecular Diagnostics pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than Insight Molecular Diagnostics quarterly revenues of $2.1M. Veracyte's net income of $7M is higher than Insight Molecular Diagnostics's net income of -$6.7M. Notably, Veracyte's price-to-earnings ratio is 64.37x while Insight Molecular Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.50x versus 19.22x for Insight Molecular Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 6.16% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of 2.85% beat ProPhase Labs's return on equity of -144.22%.

Veracyte has a consensus price target of $40.89, signalling upside risk potential of 54.94%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3900%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

Veracyte has a beta of 2.093, which suggesting that the stock is 109.267% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.433, suggesting its less volatile than the S&P 500 by 143.298%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Veracyte's net income of $7M is higher than ProPhase Labs's net income of $4M. Notably, Veracyte's price-to-earnings ratio is 64.37x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.50x versus 1.87x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 6.16% compared to Veracyte's net margin of -67.19%. Veracyte's return on equity of 2.85% beat XWELL's return on equity of -153.74%.

Veracyte has a consensus price target of $40.89, signalling upside risk potential of 54.94%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 636.92%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

Veracyte has a beta of 2.093, which suggesting that the stock is 109.267% more volatile than S&P 500. In comparison XWELL has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.658%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $114.5M, which are larger than XWELL quarterly revenues of $7M. Veracyte's net income of $7M is higher than XWELL's net income of -$4.7M. Notably, Veracyte's price-to-earnings ratio is 64.37x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 4.50x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.